Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ-B3101) in Pediatric Patients With Relapsed/Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma: A Phase I Study.
- DOI
- 10.1002/mco2.71128
- Published
- 2026 Nov
- Container
- MedComm
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/mco2.71128,
title = {Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ-B3101) in Pediatric Patients With Relapsed/Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma: A Phase I Study.},
author = {Lu S and Huang J and Cai R and Gao Y and Zhu J and Wang J and Que Y and Zhen Z and Sun F and Huang H and Zhang Y},
year = {2026},
journal = {MedComm},
doi = {10.1002/mco2.71128},
url = {https://doi.org/10.1002/mco2.71128}
}RIS
TY - JOUR TI - Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ-B3101) in Pediatric Patients With Relapsed/Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma: A Phase I Study. AU - Lu S AU - Huang J AU - Cai R AU - Gao Y AU - Zhu J AU - Wang J AU - Que Y AU - Zhen Z AU - Sun F AU - Huang H AU - Zhang Y PY - 2026 JO - MedComm DO - 10.1002/mco2.71128 UR - https://doi.org/10.1002/mco2.71128 ER -
APA
S, L., J, H., R, C., Y, G., J, Z., J, W., Y, Q., Z, Z., F, S., H, H., & Y, Z. (2026). Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ-B3101) in Pediatric Patients With Relapsed/Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma: A Phase I Study.. MedComm. https://doi.org/10.1002/mco2.71128
Source records
- pubmed · retrieved 2026-11-10T07:59:35.181Z